Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment.

Pubmed ID: 23861441

Pubmed Central ID: PMC3717474

Journal: BMJ open

Publication Date: July 15, 2013

Affiliation: Huntsman Cancer Institute at the University of Utah, St Louis, Missouri, USA.

Authors: Hartz A, He T, Wallace R, Powers J

Cite As: Hartz A, He T, Wallace R, Powers J. Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment. BMJ Open 2013 Jul 15;3. (7). Print 2013.

Studies:

Abstract

OBJECTIVES: Prospective observational studies (OSs) that collect adequate information about confounders can validly assess treatment consequences. However, what constitutes adequate information is unknown. This study investigated whether the extensive information collected by the Women's Health Initiative (WHI) in two OSs and two randomised controlled trials (RCTs) was adequate. DESIGN: Secondary analysis of WHI data. Cox regression was used to select from all baseline risk factors those that best predicted outcome. Cox regression that included these risk factors was used for two types of analyses: (1) comparing RCT and OS assessments of the effects of hormone therapy on outcome for participants with specific characteristics and (2) evaluating whether adjustment for measured confounders could eliminate outcome differences among datasets. SETTING: The WHI included more than 800 baseline risk factors and outcomes during a median follow-up of 8 years. PARTICIPANTS: 151 870 postmenopausal women ages 50-79. PRIMARY AND SECONDARY OUTCOME MEASURES: Myocardial infarction and stroke. RESULTS: RCT and OS results differed for the association of hormone therapy with outcome after adjusting for confounding factors and stratifying on factors that were hypothesised to modulate the effects of hormone therapy (eg, age and time since menopause) or that empirically modulated the effects of hormone therapy in this dataset (eg, blood pressure, previous coronary revascularisation and private medical insurance). Some of the four WHI datasets had significantly worse outcomes than others even after adjusting for risk and stratifying by type of hormone therapy, for example, the risk-adjusted HR for myocardial infarction was 1.37 (p<0.0001) in an RCT placebo group compared with an OS group not taking hormone therapy. CONCLUSIONS: Apparently the WHI did not collect sufficient information to give reliable assessments of treatment effects. If the WHI did not collect sufficient data, it is likely that few OSs collect sufficient information.